NFE2L2 and non-small cell lung carcinoma: In addition, CB-839 is also being tested in a phase II randomized trial (NCT04265534) to compare it with chemotherapy and pembrolizumab as standard-of-care in patients with advanced KEAP1-NFE2L2 mutant non-squamous NSCLC.